Oddo BHF maintains its 'outperform' rating on Valbiotis shares, with a target price raised from 10 to 11.5 euros.

As a reminder, earlier this week Valbiotis published its Phase II/III clinical results for TOTUM-63 in pre-diabetes. These proved positive, demonstrating a statistically significant reduction in fasting glycemia in patients vs. placebo.

According to Oddo BHF, TOTUM-63 is already scheduled to be marketed in 2024, given its health nutrition status, in collaboration with Nestlé Health Science.

We now see the clinical and regulatory aspects as secure. Given its profile, Valbiotis combines the opportunities of a biotech company with a lower development risk, which makes it even more attractive", concludes the broker.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.